TABLE 2.
Anti–PD-1/PD-L1 Antibodies Most Frequently Observed or Notable Drug-Related* AEs
| AE | Nivolumab25,47,55 | Pembrolizumab56,57 | MPDL3280A58,59 | BMS-93655922 |
|---|---|---|---|---|
| Any | 70%–84% | 47%–79% | NR | 61% |
| Drug-related grade 3 or 4 | 14%–22% | 13% | 13%–14% | 9% |
| Drug-related severe AEs | 11%–21% | NR | NR | 5% |
| Tx d/c due to AEs | 5%–9% | NR | NR | 6% |
| Fatigue | 9%–32% | 12%–30% | 35%–59% | 16% |
| Rash | 9%–23% | 21% | 16%–20% | 7%–9% |
| Diarrhea | 9%–18% | 6%–20% | 22%–30% | 9% |
| Pruritus | 10%–18% | 21%–24% | 25% | 6% |
| Decreased appetite/anorexia | 3%–8% | 4% | 18%–21% | 3% |
| Nausea | 3%–8% | 10%–12% | 20%–23% | 6% |
| Elevated lipase | 12% | NR | NR | NR |
| Fever/pyrexia | 1%–5% | 7% | 21%–26% | 3% |
| Chills | NR | 7% | 16%–18% | 1% |
| Asthenia | NR | 10% | NR | NR |
| Infusion reactions | 2%–6% | NR | NR | 10% |
| Arthralgia | 3%–7% | 15% | 16%–33% | 7% |
| Cough | 3%–6% | 8% | 21%–27% | NR |
| Constipation | NR | 3% | 21%–22% | NR |
| Back pain | NR | 2% | 18% | NR |
| Dyspnea | NR | 4% | 18%–23% | NR |
| Headache | 3% | 10% | 16%–32% | 9% |
*
With the exception of the MPDL3280A data, the AEs are treatment related. Thus, the higher percentages in the MPDL3280A data in part reflect reporting of both related and unrelated AEs.
d/c Indicates discontinuation; NR, not reported; Rel, related; Tx, treatment.